Terms: = Ovarian cancer AND RUNX1T1, ENSG00000079102, 862 AND Prognosis
6 results:
1. Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response.
Chen J; Chen S; Dai X; Ma L; Chen Y; Bian W; Sun Y
Front Immunol; 2022; 13():1007326. PubMed ID: 36189254
[TBL] [Abstract] [Full Text] [Related]
2. A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis.
Yang L; Yu J; Zhang S; Shan Y; Li Y; Xu L; Zhang J; Zhang J
J Ovarian Res; 2022 Feb; 15(1):26. PubMed ID: 35168642
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Analysis of Tripterine Anti-ovarian cancer Effects Using Weighted Gene Co-Expression Network Analysis and Molecular Docking.
Long X; Liu L; Zhao Q; Xu X; Liu P; Zhang G; Lin J
Med Sci Monit; 2022 Jan; 28():e932139. PubMed ID: 35022380
[TBL] [Abstract] [Full Text] [Related]
4. Long non-coding RNA EPB41L4A-AS2 suppresses progression of ovarian cancer by sequestering microRNA-103a to upregulate transcription factor runx1t1.
Sun T; Yang P; Gao Y
Exp Physiol; 2020 Jan; 105(1):75-87. PubMed ID: 31645082
[TBL] [Abstract] [Full Text] [Related]
5. Expression Patterns of Nrf2 and Keap1 in ovarian cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
Cho HY; Kim K; Kim YB; Kim H; No JH
Int J Gynecol Cancer; 2017 Mar; 27(3):412-419. PubMed ID: 28129239
[TBL] [Abstract] [Full Text] [Related]
6. Preoperative fluorine 18 fluorodeoxyglucose tumoral uptake ratio between upper and lower abdomen in primary advanced-stage ovarian cancer.
Shim SH; Kim DY; Seo MJ; Lee SW; Park JY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2013 Oct; 23(8):1383-92. PubMed ID: 24257552
[TBL] [Abstract] [Full Text] [Related]
